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Learning Objectives
===================

Upon completion of this activity, participants will be able to:

-   Identify the classes of antimicrobial drugs most commonly used in Europe.

-   Describe patterns of antimicrobial drug use across regions in Europe.

-   Identify the most widely used antimicrobial drugs by country in Europe.

-   List European countries that show the highest antimicrobial drug resistance proportions.

-   Describe the association between antimicrobial drug use and the emergence of resistance.
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CME Questions
=============

1.  Which of the following classes of antimicrobial drugs is least likely to be used in European countries?

    1.  A. Lincosamides

    2.  B. Fluoroquinolones

    3.  C. Cotrimoxazole

    4.  D. Macrolides

2.  Which of the following regions in Europe has the highest outpatient utilization of antimicrobial drugs?

    1.  A. Southern

    2.  B. Northern

    3.  C. Eastern

    4.  D. Central

3.  Which of the following is the most widely used antimicrobial drug class in Europe?

    1.  A. Macrolides

    2.  B. Penicillins

    3.  C. Nonpenicillin beta-lactams

    4.  D. Fluoroquinolones

4.  Which of the following European countries showed both the greatest use of antimicrobial drugs in ambulatory care and the highest resistance proportions?

    1.  A. France

    2.  B. Croatia

    3.  C. Italy

    4.  D. Greece

5.  Among European countries with high antimicrobial drug resistance rates, a robust and consistent association was most likely to be found between utilization and resistance for which of the following drugs?

    1.  A. Penicillins and macrolides

    2.  B. Lincosamides and macrolides

    3.  C. Penicillins and streptogramins

    4.  D. Penicillins and fluoroquinolones
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